Two Anapen doses soon to be discontinued

Healthed

writer

Healthed

Healthed

Anapen® Junior 150 and Anapen® 300 will no longer be sold or distributed in Australia, “due to lack of demand for a second brand of adrenaline autoinjector for the 150mcg and 300mcg strengths,” its manufacturer announced this week.

“This decision is voluntary and not related to any quality, safety or efficacy issues regarding the products,” Arrotex Pharmaceuticals general manager for marketing said in a letter to health professionals, adding that the company will focus instead on the 500mcg strength.

The Anapen® Junior 150 will be available until the end of September 2024, while Anapen® 300 will only be available until the end of July 2024. Both products are ‘a’ flagged to their EpiPen equivalent, so after these dates pharmacists can substitute with EpiPen Junior and EpiPen2 (with appropriate training).

Anapen® 500 and Anapen® Trainer devices will remain available. Arrotex has reassured the public that it will continue to supply Anapen® 500, which is the only 500mcg adrenaline autoinjector available on the PBS.

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Dr Jo-Ann See

Dr Jo-Ann See

Management of Acne in Teens

Dr Robert Hungerford

Dr Robert Hungerford

An Update on Heart Failure in General Practice

Dr Michael Selby

Dr Michael Selby

Scoliosis in Children: Preventing Surgery

A/Prof Yvonne Zissiadis

A/Prof Yvonne Zissiadis

Innovations in Breast Radiation

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Once you confirm you’ve read this article you can complete a Patient Case Review to earn 0.5 hours CPD in the Reviewing Performance (RP) category.

Select ‘Confirm & learn‘ when you have read this article in its entirety and you will be taken to begin your Patient Case Review.

I invite you to join the upcoming Healthed webcast where I will give an update on current radiation therapy regimens and the potential side effects of this treatment. In addition, I will present the latest learnings from breast cancer research, including the increasing recognition of the value of exercise as part of effective breast cancer management.

Tuesday 5th August, 7pm AEST